NEOPROFEN (Ibuprofen Lysine) Patent Expiration, LOE Window & CMS Spending
NEOPROFEN (Ibuprofen Lysine) by Recordati Rare Diseases: FDA Orange Book core substance LOE 2032-03-02, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Recordati Rare Diseases |
| FDA Application & Pathway | N021903 (NDA) |
| Exclusivity / Cliff Horizon | Mid-Term Protection (2031-2035) |
| Core Active-Ingredient LOE Date | 2032-03-02 |
| Last Listed Patent or Exclusivity Date | 2032-03-02 |
| Orange Book Patents (*PED Extensions) | 1 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | 1 WAC filings (max 32.5% 2-yr change) |